UBS raised the firm’s price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

(NASDAQ:ETNB – Get Free Report) had its price target boosted by stock analysts at UBS Group from $25.00 to $38.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a ...

Shares of 89bio, Inc. (NASDAQ:ETNB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports.

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

BofA Securities has recently resumed 89bio Inc (ETNB) stock to Buy rating, as announced on April 22, 2024, according to Finviz. Earlier, on January 12, 2024, RBC Capital Mkts had reduced the stock ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

89bio, Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of ...

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...